Bone mineral density in systemic sclerosis;Densidade mineral ossea na esclerose sistemica

Revista Brasileira de Reumatologia

Volumn 40, Issue 4, 2000, Pages 153-158

  Sampaio Barros, P D ^a   De Paiva Magalhaes, E ^a   Sachetto, Z ^a   Samara, A M ^a   Marques Neto, J F ^a  

^a NONE   (Brazil)

Author keywords

Bone mineral density; Menopause; Osteoporosis; Systemic scleroderma

Indexed keywords

BONE MINERAL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; PENICILLAMINE;

ABSORPTIOMETRY; ADULT; ARTICLE; BONE DEMINERALIZATION; BONE DENSITY; CAUCASIAN; DISEASE ASSOCIATION; DISEASE DURATION; DRUG USE; FEMUR NECK; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUMBAR SPINE; MAJOR CLINICAL STUDY; MENOPAUSE; OSTEOPOROSIS; RACE DIFFERENCE; SYSTEMIC SCLEROSIS;

EID: 0033795761     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Epidemiology of osteoporosis
2. The effects of systemic lupus erythematosus and long-term steroid therapy on bone mass in pre-menopausal women
3. Prevalence of reduced bone mineral density in systemic lupus erythematosus and the role of steroids
4. Osteoporosis in juvenile systemic lupus erythematosus: A longitudinal study on the effect of steroids on bone mineral density
5. Bone metabolism and bone mineral density of systemic lupus erythematosus at the time of diagnosis
6. Determinants of bone mass in systemic lupus erythematosus: A cross-sectional study of premenopausal women
7. Should we look for osteoporosis in patients with rheumatoid arthritis?
8. Bone mineral density in patients with recent onset rheumatoid arthritis: Influence of disease activity and functional capacity
9. Generalized bone loss in patients with early rheumatoid arthritis
10. Rheumatoid arthritis, corticosterold therapy and hip fracture
11. Evaluation of bone mineral density in patients with rheumatoid arthritis. Influence of disease activity and glucocorticoid therapy
12. Systemic osteopenia and mineralization defect in patients with ankylosing spondylitis
13. Appendicular and vertebral bone mass in ankylosing spondylitis
14. Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis
15. Influence of disease activity and chronicity on ankylosing spondylitis bone mass loss
16. Osteoporosis, body composition, and bone turnover in ankylosing spondylitis
17. L'osteoporose de la spondylarthrite ankylosante
18. Epidemiology of scleroderma
19. Epidemiology and natural history of systemic sclerosis
20. Osteopenia in systemic sclerosis. Evidence of a participating role of earlier menopause
21. Reduced bone mass and normal calcium metabolism in systemic sclerosis with and without calcinosis
22. Estudo da densidade ossea na esclerodermia sistemica
23. Preliminary criteria for the classification of systemic sclerosis (scleroderma)
24. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis
25. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis
26. Limited bone loss due to corticosteroids; a systematic review of prospective studies in rheumatoid arthritis and other diseases
27. A UK consensus group on management of glucocorticoid-induced osteoporosis: An update
28. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis
29. Uso da ciclofosfamida endovenosa na esclerose sistemica
30. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy
31. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide
32. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy
33. A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine